Citations

Showing 10 of 108104 citations.

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
Castillo, Jorge J. , Paludo, Jonas , Varettoni, Marzia , Buske, Christian , Eyre, Toby A. , Chávez, Julio C. , Shain, Kenneth H. , Issa, Samar , Palomba, M. Lia , Pasvolsky, Oren , Simpson, David , Talaulikar, Dipti , Tedeschi, Alessandra , Ansell, Stephen M. , Nayak, Lakshmi , Paludo, Jonas , Buske, Christian , Eyre, Toby A , Chavez, Julio C , Palomba, M Lia , Talaulikar, Dipti , Tam, Constantine S , Tedeschi, Alessandra , Ansell, Stephen M , Treon, Steven , Castillo, Jorge J , Itchaki, Gilad , Tam, Constantine S. , Treon, Steven P. , Varettoni, Marzia , Pasvolsky, Oren

Mayo Clinic

Blood | December 6, 2018 | Volume: 133 | Issue: 4 | Pages: 299-305

10.1182/blood-2018-10-879593 | PMID 30523119 Get It

Abstract The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Survival from BNS diagnosis (BNS survival), survival from ibrutinib initiation to last follow-up or death (ibrutinib survival), and time from ibrutinib initiation to ibrutinib discontinuation for toxicity, progression, or death (event-free survival [EFS]) were estimated. Twenty-eight patients were included in our study. The median age at BNS diagnosis was 65 years. Ibrutinib was the first line of treatment for BNS in 39% of patients. Ibrutinib was administered orally at a dose of 560 and 420 mg once daily in 46% and 54% of patients, respectively; symptomatic and radiologic improvements were seen in 85% and 60% of patients within 3 months of therapy. At best response, 85% of patients had improvement or resolution of BNS symptoms, 83% had improvement or resolution of radiologic abnormalities, and 47% had cleared the disease in the cerebrospinal fluid. The 2-year EFS rate with ibrutinib was 80% (95% confidence interval [CI], 58%-91%), the 2-year ibrutinib survival rate was 81% (95% CI, 49%-94%), and the 5-year BNS survival rate was 86% (95% CI, 63%-95%). Ibrutinib therapy is effective in patients with BNS and should be considered as a treatment option in these patients.
Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features
Wu, Jiang , Cai, Muyan , Li, Shiyong , Bei, Jin‐Xin , Wang, Fang , Ling, Yihong , Rodrı́guez-Bigas, Miguel A. , Dignam, James J. , Mao, Mao , Li, Jibin , Guo, Yun‐Miao , Wu, Xiaoyan , Kong, Lingheng , Tang, Jing‐Hua, Li, Chao‐Feng, Chen, Jie‐Rong, Ye, Ming‐Zhi, Guo, Fengming, Han, Peng , Wan, Desen, Li, Li , Xu, Rui‐Hua , Ding, Pei-Rong , Group, Written on behalf of AME Colorectal Cancer Cooperative, Xu, Rui‐Hua , Jiang, Wu , Xu, Rui-Hua , Hampel, Heather , Frayling, Ian M. , Sinicrope, Frank A. , Kerr, David , Rosell, Rafael , Kong, Ling‐Heng, Tang, Jing-Hua , Wu, Xiaodan , Ou, Qingjian , Ye, Ming-Zhi, Wang, Qiwei , Pan, Zhizhong , Group, Written on behalf of AME Colorectal Cancer Cooperative

Mayo Clinic

International Journal of Cancer | December 6, 2018 | Volume: 144 | Issue: 9 | Pages: 2161-2168

10.1002/ijc.32044 | PMID 30521064 Get It

The prevalence of Lynch syndrome (LS) varies significantly in different populations, suggesting that ethnic features might play an important role. We enrolled 3330 consecutive Chinese patients who had surgical resection for newly diagnosed colorectal cancer. Universal screening for LS was implemented, including immunohistochemistry for mismatch repair (MMR) proteins, BRAFV600E mutation test and germline sequencing. Among the 3250 eligible patients, MMR protein deficiency (dMMR) was detected in 330 (10.2%) patients. Ninety‐three patients (2.9%) were diagnosed with LS. Nine (9.7%) patients with LS fulfilled Amsterdam criteria II and 76 (81.7%) met the revised Bethesda guidelines. Only 15 (9.7%) patients with absence of MLH1 on IHC had BRAFV600E mutation. One third (33/99) of the MMR gene mutations have not been reported previously. The age of onset indicates risk of LS in patients with dMMR tumors. For patients older than 65 years, only 2 patients (5.7%) fulfilling revised Bethesda guidelines were diagnosed with LS. Selective sequencing of all cases with dMMR diagnosed at or below age 65 years and only of those dMMR cases older than 65 years who fulfill revised Bethesda guidelines results in 8.2% fewer cases requiring germline testing without missing any LS diagnoses. While the prevalence of LS in Chinese patients is similar to that of Western populations, the spectrum of constitutional mutations and frequency of BRAFV600E mutation is different. Patients older than 65 years who do not meet the revised Bethesda guidelines have a low risk of LS, suggesting germline sequencing might not be necessary in this population.
Identifying and Mitigating Design Challenges of Ophthalmology Tele-medicine at Mayo Clinic
Gaffar, Ashraf, Patel, Dharmendra, Pallagi, Peter J. , Gaffar, Rouan, Karami, Mansooreh

Mayo Clinic

2017 International Conference on Computational Science and Computational Intelligence (CSCI) | December 6, 2018 | Volume: No volume available | Issue: No issue available | Pages: 1732-1736

10.1109/csci.2017.301 Get It

A Tele-triage Application Design for Mobile Health at Mayo Clinic
Gaffar, Ashraf, Patel, Dharmendra, Pallagi, Peter J. , Gaffar, Rouan, Karami, Mansooreh

Mayo Clinic

2017 International Conference on Computational Science and Computational Intelligence (CSCI) | December 6, 2018 | Volume: No volume available | Issue: No issue available | Pages: 1720-1725

10.1109/csci.2017.299 Get It

Abstract P274: Endothelial Dysfunction of Conduit Arteries in Amyloid Precursor Protein-Deficient Mice
Katušić, Zvonimir S. , d’Uscio, Livius V.

Mayo Clinic

Hypertension | December 6, 2018 | Volume: 72 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.72.suppl_1.p274 Get It

Amyloid precursor protein (APP) is an integral membrane protein expressed in the peripheral arteries. However, the exact vascular physiological function of APP is unknown. Male APP-deficient (APP –/– ) and their wild-type littermates (WT) mice were used to characterize the phenotype of APP in the control of vascular function. Isometric force of isolated aortic rings was recorded in organ chambers. Circulating levels of norepinephrine and epinephrine were significantly enhanced in APP –/– mice (4723±566 pg/mL and 854±98 pg/mL, respectively P<0.05 vs. WT: 1999±319 pg/mL and 429±71 pg/mL, respectively; n=13). The efficacy of phenylephrine induced contractions were significantly reduced in the aorta of APP –/– mice (21±3%, P<0.05 vs. WT: 47±4%; n=10) while contractions to prostaglandin F 2α were unchanged (135±4%, P=n.s. vs. WT: 133±3%; n=9). Western blot analysis revealed that protein expression of alpha1D adrenergic receptors was significantly downregulated in APP –/– mice aortas (0.21±0.05 O.D.; P<0.05 vs. WT: 0.48±0.11 O.D.; n=6). In contrast, endothelium-dependent relaxations to β-agonist isoproterenol were significantly enhanced in APP –/– mice aortas (P<0.05; n=10) while endothelium-dependent relaxations to acetylcholine were unaltered (P=n.s.; n=12). Incubation of aortic rings with indomethacin significantly impaired relaxations to isoproterenol as well as acetylcholine in APP –/– mice (P<0.05; n=8) while concomitant treatment with NOS inhibitor L-NAME completely abolished relaxations to both agonists (P<0.05; n=6-7). Incubation of aortic rings with isoproterenol significantly increased cAMP in the aortas of APP –/– mice (16.2±4.1 pmol/mg; P<0.05 vs. WT: 6.6±4.1 pmol/mg; n=7). Furthermore, cAMP levels were significantly enhanced by acetylcholine in APP –/– mice aortas (38±9 pmol/mg; P<0.05 vs. WT: 14±3 pmol/mg; n=8) while acetylcholine stimulated cGMP levels were reduced (59±5 pmol/mg; P<0.05 vs. WT: 83±7 pmol/mg; n=12). Our results suggest that increased circulating levels of catecholamines in APP –/– mice are responsible for observed vascular phenotype. These findings indicate that under physiological conditions, APP expression plays an important role in control of vascular endothelial function .
Abstract P167: Altered Gut Microbiome Contributes to Metabolite Biomarkers in Patients With Pulmonary Hypertension
Kim, Seungbum , Walejko, Jacquelyn M., Jordan, Ray, Shapiro, Brian P. , Richards, Elaine M. , Raizada, Mohan K. , Rigatto, Katya , Pepine, Carl J.

Mayo Clinic

Hypertension | December 6, 2018 | Volume: 72 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.72.suppl_1.p167 Get It

Objectives: Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease without effective cure. The objective of this study is to test the hypothesis that PAH patients have a distinct gut microbiome composition acting as a driving force for the increased PAH metabolic biomarkers, acyl carnitines and urate. Methods: Fecal samples from 18 type 1 PAH patients (mean pulmonary arterial pressure [mPAP] 57.4±16.7 mmHg) and 13 reference subjects in Brazil were collected for comparison of microbiome using shotgun metagenomics. Plasma samples from 33 type I PAH patients (mPAP 51.7± 13.5 mmHg) and 19 reference subjects in the USA were used for untargeted metabolomic analysis. Results: More than 80 bacterial taxa were differentially enriched in the microbiomes of the PAH cohort. Random forest machine-learning algorithm predicted PAH patients with 82.4% accuracy from their gut microbiome composition. The most increased taxa in the PAH microbiome were trimethylamine (TMA) producing bacteria like Collinsella (P=0.0037). The PAH metabolome also showed increases of gut microbiome-derived short chain acyl carnitines like isubutyrylcarnitine (P=0.010) and valerylcarnitine (P=0.030), which are the precursors of TMA. In addition, increased urate (P=0.0004) and allantoin (P=0.027) in PAH plasma correlated with significantly increased enzymes producing urate in the PAH microbiome (purine metabolism (P=0.017) and xanthine oxidase (P<0.05)). Conclusion: These findings suggest that the random forest modeling of the gut microbiome composition can be used for prediction of PAH and that the unique gut microbiome of PAH influences acyl carnitines and urate metabolism to contribute to pathophysiology.
Abstract 124: Nadph Oxidase 4 and Mitochondrial Abnormalities Contribute to Oxidative Stress and Endothelial Dysfunction in Young Normotensive Patients With Autosomal Dominant Polycystic Kidney Disease
Kahveci, Ali, Lerman, Lilach O. , Chebib, Fouad T. , Eirin, Alfonso , Lerman, Amir , Harris, Peter C. , Torres, Vicente E. , Irazabal, María V.

Mayo Clinic

Hypertension | December 6, 2018 | Volume: 72 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.72.suppl_1.124 Get It

Background: Fifty percent of patients with autosomal dominant polycystic kidney disease (ADPKD) present hypertension (HTN) early on, which increases to nearly 100% at end-stage, and is associated with faster renal functional decline. Endothelial dysfunction (ED) accompanied by oxidative stress (OS) precedes the development of HTN, but the mechanisms responsible remain unknown. The aim of this study was to determine whether NADPH oxidase (NOX4) and mitochondrial dysfunction contribute to OS and ED preceding HTN in early ADPKD. Methods: We prospectively measured plasma levels of homocysteine (Hcy), 8-isoprostane, NOX4 and the mtDNA genes COX3 and ND1 in young normotensive (without BP medication) ADPKD patients, and age-matched healthy volunteers (HV) (n=10, each). Total kidney volume (TKV) and Renal Blood Flow (RBF) were evaluated by MRI. Results: BP levels were higher in ADPKD, and HtTKV was twofold higher in ADPKD vs. controls. eGFR and RBF were similar between the groups (Table). Plasma Hcy, 8-isoprostanes and NOX4 were higher in ADPKD, and correlated directly with HtTKV (p<0.05, Figure), but the correlation with RBF was not significant. Plasma mtDNA copy number were lower in ADPKD compared to controls, and correlated inversely with HtTKV(R 2 0.397 and 0.392 respectively). Conclusion: Early ADPKD is associated with elevation in Hcy, 8-isoprostane, and NOX4 levels, and decreased mtDNA copy numbers, which precede the reduction in RBF and the development of HTN, and are associated with disease severity. NOX4 and mitochondrial abnormalities may contribute to oxidative stress, endothelial dysfunction, and possibly the development of HTN and disease progression in ADPKD.
Abstract 063: Urinary Mitochondrial DNA Copy Number Identifies Renal Mitochondrial Injury in Renovascular Hypertensive Patients Undergoing Renal Revascularization
Lerman, Lilach O. , Eirin, Alfonso , Herrmann, Sandra M. , Saad, Ahmed , Tang, Hui Jun , Lerman, Amir

Mayo Clinic

Hypertension | December 6, 2018 | Volume: 72 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.72.suppl_1.063 Get It

Background: We have previously shown in patients with renovascular hypertension (RVH) that elevated urinary mtDNA copy numbers represent surrogate markers of renal mitochondrial injury. Revascularization with percutaneous transluminal renal angioplasty (PTRA) can lead to acute renal reperfusion injury. However, whether PTRA induces renal mitochondrial injury remains unknown. Methods: We prospectively measured urinary copy number of the mtDNA genes cytochrome-c oxidase-3 (COX3) and NADH dehydrogenase subunit-1 (ND1) by qPCR in 5 RVH patients before and 24hrs after PTRA. Five additional patients were treated before and during PTRA with the mitoprotective drug elamipretide (ELAM, 0.05 mg/kg/hr IV infusion). Healthy volunteers (HV) served as controls (n=5). Results: Baseline blood pressure was similarly elevated in both RVH groups, and eGFR lower than HV (Table). Baseline urinary COX3 and ND1 levels were similarly higher in both RVH groups compared with HV (Fig. A), and directly correlated with serum creatinine levels (R 2 =0.74, p=0.001 and R 2 =0.45, p=0.033, respectively). Over 3 months, eGFR increased only in ELAM-treated patients (Fig. B). Furthermore, the rise in urinary mtDNA 24hrs after PTRA was blunted in PTRA+ELAM versus PTRA+Placebo, and inversely correlated with the change in eGFR of 3 months after PTRA (Fig. C). Conclusion: PTRA induces an acute rise in urinary mtDNA levels, likely reflecting renal mitochondrial injury due to reperfusion injury that inhibits renal recovery. Mitoprotection in this cohort limited PTRA-associated mitochondrial injury and improved renal outcomes after revascularization.
Predicting Progression to Mild Cognitive Impairment
Petersen, Ronald C. , Lundt, Emily S. , Therneau, Terry M. , Weigand, Stephen D. , Roberts, Rosebud O., Lowe, Val J. , Kremers, Walter K. , Geda, Yonas E. , Jack, Clifford R. , Jack, Clifford R , Geda, Yonas E , Kremers, Walter K , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M. , Lundt, Emily S

Mayo Clinic

Annals of Neurology | December 6, 2018 | Volume: 85 | Issue: 1 | Pages: 155-160

10.1002/ana.25388 | PMID 30521086 Get It

Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population‐based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75‐year‐old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.
Cloning, function, and localization of human, canine, and Drosophila ZIP10 (SLC39A10), a Zn2+ transporter
Landry, Greg M. , Furrow, Eva , Holmes, Heather L. , Hirata, Taku, Kato, Akira , Williams, Paige E., Strohmaier, Käri, Gallo, C. , Chang, Min‐Hwang , Pandey, Mukesh K. , Bansal, Aditya , Franz, Marie-Christine, Montalbetti, Nicolás , Alexander, Mariam P., Cabrero, Pablo , Dow, Julian A. T. , DeGrado, Timothy R. , Romero, Michael F. , Williams, Paige, Gallo, Chris J R, Chang, Minhwang, Jiang, Huailei , Dow, Julian A T , Romero, Michael F , Kato, Akira , Pandey, Mukesh K , Williams, Paige, Franz, Marie-Christine

Mayo Clinic

American Journal of Physiology-Renal Physiology | December 6, 2018 | Volume: 316 | Issue: 2 | Pages: F263-F273

10.1152/ajprenal.00573.2017 | PMID 30520657 Get It

Zinc (Zn2+) is the second most abundant trace element, but is considered a micronutrient, as it is a cofactor for many enzymes and transcription factors. Whereas Zn2+ deficiency can cause cognitive immune or metabolic dysfunction and infertility, excess Zn2+ is nephrotoxic. As for other ions and solutes, Zn2+ is moved into and out of cells by specific membrane transporters: ZnT, Zip, and NRAMP/DMT proteins. ZIP10 is reported to be localized at the apical membrane of renal proximal tubules in rats, where it is believed to play a role in Zn2+ import. Renal regulation of Zn2+ is of particular interest in light of growing evidence that Zn2+ may play a role in kidney stone formation. The objective of this study was to show that ZIP10 homologs transport Zn2+, as well as ZIP10, kidney localization across species. We cloned ZIP10 from dog, human, and Drosophila ( CG10006), tested clones for Zn2+ uptake in Xenopus oocytes and localized the protein in renal structures. CG10006, rather than foi (fear-of-intimacy, CG6817) is the primary ZIP10 homolog found in Drosophila Malpighian tubules. The ZIP10 antibody recognizes recombinant dog, human, and Drosophila ZIP10 proteins. Immunohistochemistry reveals that ZIP10 in higher mammals is found not only in the proximal tubule, but also in the collecting duct system. These ZIP10 proteins show Zn2+ transport. Together, these studies reveal ZIP10 kidney localization, a role in renal Zn2+ transport, and indicates that CG10006 is a Drosophila homolog of ZIP10.